Aquestive therapeutics receives fda fast track designation for aqst-109 for emergency treatment of allergic reactions including anaphylaxis

Warren, n.j., march 17, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq:aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that the u.s. food and drug administration (fda) has granted fast track designation to aqst-109, the first and only orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis.
AQST Ratings Summary
AQST Quant Ranking